Related references
Note: Only part of the references are listed.Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
Alessandro Nepote et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Recent advances in B-RAF inhibitors as anticancer agents
Pathan Shahebaaz Khan et al.
BIOORGANIC CHEMISTRY (2022)
Improving virtual screening results with MM/GBSA and MM/PBSA rescoring
Harutyun Sahakyan
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2021)
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
Malcolm P. Huestis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution
Chuan Tian et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2020)
Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches
Ahmed Karam Farag et al.
BIOORGANIC CHEMISTRY (2020)
2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments
Ashraf K. El-Damasy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations
Seung-Hye Choi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition
Hoyong Jung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Encorafenib and Binimetinib: First Global Approvals
Matt Shirley
DRUGS (2018)
A comprehensive review of protein kinase inhibitors for cancer therapy
Radhamani Kannaiyan et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
Jing-hua Pan et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
James Sun et al.
ONCOTARGETS AND THERAPY (2018)
Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents
Ashraf Kareem El-Damasy et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
Synthesis and biological evaluation of novel N-(5-phenyl-1H-pyrazol-3-yl)benzenesulfonamide derivatives as potential BRAFV600E inhibitors
Zhen-Hua Gong et al.
MEDICINAL CHEMISTRY RESEARCH (2017)
Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma
Yuanyuan Li et al.
MELANOMA RESEARCH (2017)
Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
Maho Takahashi et al.
MOLECULAR AND CELLULAR BIOLOGY (2017)
Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance
Lu Wang et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Jean-Pierre Delord et al.
CLINICAL CANCER RESEARCH (2017)
CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field
Jumin Lee et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening
Ashraf Kareem El-Damasy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities
Ashraf Kareem El-Damasy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
NMR Chemical Shifts of Trace Impurities: Industrially Preferred Solvents Used in Process and Green Chemistry
Nicholas R. Babij et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2016)
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents
Yu Jiao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives
Ashraf Kareem El-Damasy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer
Chun-Hui Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors
Shuai Song et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2015)
A-Raf: A new star of the family of raf kinases
Su An et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
A new series of diarylamides possessing quinoline nucleus: Synthesis, in vitro anticancer activities, and kinase inhibitory effect
Mohammed I. El-Gamal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
Huimin Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
Masanori Okaniwa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
Tara R. Rheault et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
An overview of the Amber biomolecular simulation package
Romelia Salomon-Ferrer et al.
WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE (2013)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
A Type-II Kinase Inhibitor Capable of Inhibiting the T315I Gatekeeper Mutant of Bcr-Abl
Hwan Geun Choi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Reaction of isocyanate-functionalised silicon wafers with complex amino compounds
Aurore Perzyna et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2007)
Raf kinases: Function, regulation and role in human cancer
Deborah T. Leicht et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts
K Mercer et al.
CANCER RESEARCH (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
A kinematic view of loop closure
EA Coutsias et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
